id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1995-E-0065-0003,FDA,FDA-1995-E-0065,Letter from U.S. Patent and Trademark Office to FDA Office of Health Affairs,Other,Letter(s),2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T13:24:44Z,,0,0,090000648056cd09
FDA-1995-E-0065-0004,FDA,FDA-1995-E-0065,Memorandum from FDA Office of Health Affairs to FDA DDM,Other,Memorandum,2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T13:45:21Z,,0,0,090000648056cd0a
FDA-1995-E-0065-0002,FDA,FDA-1995-E-0065,Patent Term Extension Application from Bristol-Myers Squibb Company,Other,Application,2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2018-03-20T15:03:06Z,,0,0,090000648056cd08
FDA-1995-E-0065-0006,FDA,FDA-1995-E-0065,Letter from FDA Office of Health Affairs to The Honorable Bruce Lehman,Other,Letter(s),2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T13:44:20Z,,0,0,090000648056cd0c
FDA-1995-E-0065-0008,FDA,FDA-1995-E-0065,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Bristol-Myers Squibb Company,Other,Certificate Extending Patent Term,2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T14:10:45Z,,0,0,090000648056cd0e
FDA-1995-E-0065-0007,FDA,FDA-1995-E-0065,Letter from FDA Office of Health Affairs to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T13:59:24Z,,0,0,090000648056cd0d
FDA-1995-E-0065-0005,FDA,FDA-1995-E-0065,Letter from FDA Office of Health Affairs to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T13:44:47Z,,0,0,090000648056cd0b